Results 41 to 50 of about 6,313 (203)

Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015

Indian Journal of Endocrinology and Metabolism, 2015
As injectable therapies such as human insulin, insulin analogs, and glucagon-like peptide-1 receptor agonists are used to manage diabetes, correct injection technique is vital for the achievement of glycemic control.
Nikhil Tandon, Sanjay Kalra, Yatan Pal Singh Balhara, Manash P Baruah, Manoj Chadha, Hemraj B Chandalia, Subhankar Chowdhury, Kesavadev Jothydev, Prasanna K. M. Kumar, Madhu S V, Ambrish Mithal, Sonal Modi, Shailesh Pitale, Rakesh Sahay, Rishi Shukla, Annamalai Sundaram, Ambika G Unnikrishnan, Subhash K Wangnoo   +17 more
doaj   +1 more source

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

Journal of Diabetes Investigation, 2022
We report the findings of a single‐dose, randomized, three‐period cross‐over, clinical trial in healthy Chinese individuals (n = 24) comparing the pharmacokinetics of insulin degludec/liraglutide (IDegLira) with its individual components. Furthermore, we
Hongzhong Liu, Bin Luo, Xia Chen, Steen H. Ingwersen, Ting Jia, Lisbeth Vestergård Jacobsen, Pei Hu   +6 more
doaj   +1 more source

Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials

Сахарный диабет, 2023
Initiation of insulin therapy with basal insulin analogues has become the standard of care for type 2 diabetes mellitus (T2DM). Timely administration of insulin allows not only to slow down the progression of type 2 diabetes, but also to reduce the ...
S. V. Nedogoda, I. N. Barykina, A. S. Salasyuk, V. O. Lutova, E. A. Popova   +4 more
doaj   +1 more source

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements

Therapeutic Advances in Endocrinology and Metabolism, 2018
Background: We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec.
Scott M. Pearson, Jennifer M. Trujillo
doaj   +1 more source

Modern basal insulins: an ongoing story or the start of a new era?

Сахарный диабет, 2015
Basal insulin represents an essential tool in the treatment of both type 1 and type 2 diabetes mellitus. The development of insulin analogues has improved the possibilities of diabetes treatment.
Ivan Ivanovich Dedov
doaj   +1 more source

Clinical use of insulin degludec

Diabetes Research and Clinical Practice, 2015
The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties ...
Vora, Jiten, Cariou, Bertrand, Evans, Marc, Gross, Jorge Luiz, Harris, Stewart, Landstedt-Hallin, Lena, Mithal, Ambrish, Rodriguez, Martín Rodríguez, Meneghini, Luigi   +8 more
openaire   +2 more sources

Effect of insulin glargine on cardiovascular risk analysed by mean HRV [PDF]

, 2019
Type 2 diabetes mellitus is an insidious disease that is increasingly present in geriatric population [1]. The greatest difficulty is represented by glycaemic control in geriatric patients often not very compliant with diet therapy and drug therapy.
Apicella, G., Dalmaso, S., Marchitto, N., Marcinnò, M., Petrucci, A., Raimondi, G.   +5 more
core   +1 more source

Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. [PDF]

, 2015
INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a treatment strategy for type 1 diabetes. Transition from multiple daily injection therapy (MDI; including basal-bolus regimens) to CSII is based on ...
Hovorka, R, Mohd-Thabit, HA
core   +1 more source

Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This post hoc analysis assessed efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec (icodec) versus once‐daily (OD) basal insulin comparators across different baseline glycated haemoglobin (HbA1c), body mass index (BMI) and type 2 diabetes (T2D) duration subgroups using data from five phase 3a trials of icodec in adults with
Alice Y. Y. Cheng, Gayathri Anil, Luis Canani, Siri Vinther, Ni Wang, Chantal Mathieu   +5 more
wiley   +1 more source

Insulin degludec is a new ultra-long-acting insulin analogue

Сахарный диабет, 2014
Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment.
Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova   +1 more
doaj   +1 more source